Two recent genome-wide association studies of East Asian populations revealed three genetic variants in WDFY4/LRRC18 associated with systemic lupus erythematosus (SLE). To identify the gene contributing to this disease susceptibility, we examined the mRNA expression of WDFY4 and LRRC18 in patients with SLE and healthy controls. WDFY4 was significantly downregulated in SLE patients as compared with controls. We used allelic expression and dual-luciferase assays to identify the functional variant. Transcriptional activity was lower for the rs877819A than -G allele. Electrophoretic mobility shift and supershift assays revealed that the transcription factor Yinyang1 (YY1) binds to rs877819, with lower affinity to the A allele, which explained the reduced transcriptional activity. This effect was further confirmed by YY1 small interfering RNA knockdown, overexpression and chromatin immunoprecipitation experiments. rs877819 in WDFY4 might be the functional site associated with SLE by reduced binding of YY1 and downregulating WDFY4 expression.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production, complement activation and organ failure, and is influenced by both genetic and environmental factors. 1, 2 The exact pathophysiological features of SLE are not completely understood. 3 The probability of SLE occurrence is increased 20-to 50-fold among first-degree relatives as compared with the general population. The concordance of the disease in monozygotic twins is B24-69% and only 2-9% in dizygotic twins. [4] [5] [6] Therefore, the genetic factors have a significant role in the pathogenesis of SLE. The genes related to SLE are increasingly being identified in various populations, [7] [8] [9] although research into their functional aspects is rare.
Recently, two genome-wide association studies (GWAS) of Asian populations identified three single-nucleotide polymorphisms (SNPs) in WDFY4, rs877819, rs7097397 and rs1913517, which was found to be related to SLE. 10, 11 rs1913517 is located in LRRC18, in an intron of WDFY4. However, little is known about the role of WDFY4 and LRRC18 as the risk factors of susceptibility to SLE.
Here, we confirmed the decreased expression of WDFY4 in SLE patients, and demonstrated that the intronic rs877819 may be the causal variant that changes the binding affinity of a regulatory transcription factor to downregulate WDFY4 expression.
RESULTS
Resequencing coding sequence of WDFY4 for rare variant Although GWAS have identified common variants for complex diseases, the common variants explain only a small fraction of the phenotypic variation, and the rare variants with a large effect might help predict individual risk. Because a rare variant in WDFY4 might have a functional effect on SLE susceptibility, we sequenced all 61 coding exons of WDFY4 in 70 normal individuals but found no novel variants in coding sequences. Our sample size has the power of 76 and 94% for detecting the rare variants with minor allele frequency 41% and 2%, respectively.
Expression of WDFY4 and LRRC18 in peripheral blood mononuclear cells from patients with SLE and healthy controls The susceptibility SNP rs1913517 is located in an intron in LRRC18, which itself is located in an intron of WDFY4 ( Figure 1a) ; thus which gene is directly associated with SLE is unclear. To identify the susceptibility gene, we examined the mRNA levels of the two genes in peripheral blood mononuclear cell (PBMC) samples from 58 SLE patients and 58 healthy controls. Relative WDFY4 mRNA expression was lower in patients with SLE than controls, with no significant difference between the groups in LRRC18 expression (Figures 1b and c) .
Identifying potential causal variant among rs1913517, rs877819 and rs7097397 The relative positions of rs1913517, rs877819 and rs7097397 showing positive association with SLE in two GWAS are in Figure 1a . To identify the functional variant among these SNPs, we conducted an independent contribution analysis and ASE assay.
As compared with rs1913517, rs877819, associated with SLE with P ¼ 2.96 Â 10 , might have an independent effect with P ¼ 5.35 Â 10 À 4 in the same study. 11 Conditional logistic regression revealed rs877819 with an independent contribution, at P ¼ 2.5 Â 10 , when controlling for rs1913517. However, rs1913517 did not have an independent effect with P ¼ 0.7758 when controlling for rs877819. Also, imputation results showed that rs877819 has one of the most significant association of P-values, which is much better than those from the other two SNPs described in this study as well as previous studies on this locus (Supplementary Figure 1) .
Next, we genotyped healthy control samples for rs877819 and rs7097397. To detect whether WDFY4 expression was associated with rs877819 or rs7097397, we performed ASE assay of 31 healthy subjects heterozygous for rs7097397 by using pyrosequencing, for it is located at the transcript sequence. Most of the mean values of A/(G þ A) ratios were between 0.4 and 0.6, with no significant difference in expression between the two alleles of rs7097397 (Figure 2a) .
To determine whether intronic rs877819 was associated with WDFY4 and LRRC18 expression, we compared the expression of subjects with different genotypes on the SNP. Because of its low An intronic variant associated with SLE H Zhao et al frequency, the AA genotype (only two samples) was not included in the analysis. Quantitative PCR analysis showed no difference on LRRC18 expression, but significantly lower WDFY4 expression was seen in AG heterozygotes than in GG homozygotes (Po0.0001, Figures 2b and c) . Thus, subjects with SLE carrying risk allele A may have a significantly lower WDFY4 expression than those with the G allele. In addition, the ancestral allele G of rs877819 is conserved among human, gorilla and mouse, which also suggests that the variant site might be functional (Figure 3) .
Comparison of the relative transcription activity of the two rs877819 alleles Although rs877819 is located in an intron, an intronic SNP might still affect gene expression through transcriptional regulation. 12 To examine this possibility, we generated two luciferase reporter constructs: pGL3Pro-G or -A, which contained the pGL3-promoter, and the genomic fragment that carries, rs877819A or -G allele. HeLa and HEK-293T cells were transfected with these reporter plasmids. At 24 h after transfection, we determined luciferase activity for each reporter relative to the basal empty reporter activity. The activity was significantly lower for the construct carrying the A allele than G allele ( Figure 4 ). This finding is consistent with our observation of the rs877819 risk allele A associated with low-transcript activity and reduced WDFY4 expression.
Transcription factors binding to rs877819 and allelic difference in nuclear protein-binding affinity Gene transcription is modulated by regulatory-factor binding sites in intronic regions. 12, 13 We used electrophoretic mobility shift assay (EMSA) to investigate whether the allelic difference in transcription activity from intronic SNP might be explained by their different binding capacities for nuclear factors. We synthesized two biotin-labeled probes corresponding to the 27-bp sequence in rs877819, and used unlabeled oligonucleotides as 'competitors' (cold probe). Nuclear extracts were prepared from HeLa cells.
Probe G could form DNA-protein complexes with the nuclear extracts ( Figure 5 ). With the addition of excessive allelic competition probes in different concentrations, the band intensity was reduced in a concentration-dependent manner and abolished by 50-fold excess G, whereas inclusion of 200-fold excess competition probe A did not significantly alter the band intensity (Figure 5a ). Therefore, rs877819 could bind with some nucleoproteins, with the affinity of G higher than A. We used MatInspector (www.genomatix.de) to identify which protein(s) bind at or near rs877819 to regulate the transcription of WDFY4, and identified the transcription-factor candidates Freac2, ZBTB7 and Yinyang 1 (YY1).
To verify the predicted transcription factors, we synthesized conserved motifs for the three factors as competition probes. The detected complex was completely abrogated only by the conserved YY1 binding motif, thus YY1 might be the transcription factor binding to the rs877819 site (Figure 5b ). To further examine whether YY1 could bind to this site, we performed supershift assay with the addition of YY1 antibody, and the band disappeared (Figure 5d ). To test the specificity of this binding, we biotin-labeled the conserved YY1 binding motif as a digoxin-labeled probe, and the YY1 mutation probe with a three-base mutation that was synthesized as a competition sequence. As expected, the YY1 'hot' probe produced a band similar to that of the band described previously, and neither was affected by the mutant probe that demonstrates the binding specificity (Figure 5c ).
These DNA binding analyses indicate that endogenous YY1 protein specifically interacted with intronic rs877819 within WDFY4, with the risk-associated A allele having lower affinity than the G allele in binding to YY1, which might explain why allele A was associated with reduced WDFY4 transcription.
To establish whether the binding also occurs in vivo, we performed chromatin immunoprecipitation assay with the HeLa cell line and YY1 antibody. A pair of primers was designed to amplify a 254-bp fragment containing rs877819. YY1 bound to the rs877819 site in vivo confirms the EMSA data (Figure 5e ).
The effect of transcription factor YY1 on different alleles of rs877819 Because YY1 could bind to intronic rs877819 that was associated with WDFY4 transcription, we then wondered whether the allelic difference of rs877819 in regulatory activity was attributable to different binding affinity for YY1. We investigated whether YY1 could regulate WDFY4 transcriptional activity by binding to this SNP. YY1 small interfering RNA (siRNA) targets, and normal controls were used to transiently transfect HeLa cells, which were transfected together with the constructed vectors pGL3Enh-G and -A. As compared with the normal controls, HeLa cells with YY1 siRNA showed significantly reduced relative luciferase activity of pGL3Enh-G (Figure 6a) . However, the risk allele was not significantly affected by YY1 knockdown, which suggests that YY1 is a positive regulator of the G allele with almost no effect on the A allele.
Next, to measure the effect of YY1 overexpression on rs877819 activity, we cotransfected HeLa cells with the constructed vectors pGL3Enh-G or -A and an empty vector control (pcDNA3.1) or a YY1 expression construct (CMV-YY1). Cells transfected with CMV-YY1 constructs had a high level of YY1, for an B1.5-fold increase in relative luciferase activity with pGL3Enh-G. However, for the A allele, the relative luciferase activity did not change significantly, which was similar to the results obtained from the knockdown experiments (Figure 6b ). In addition, we cotransfected HeLa cells with pGL3Enh-G and YY1 expression constructs at different concentrations. The relative activity of G allele increased with the CMV-YY1 concentration from 20-200 ng, which further supports the role of YY1 as a positive regulation factor by binding to the G allele (Figure 6c ). Thus, YY1 had a positive role in transcription activity of the G allele from rs877819, with little role in that of the A allele. Moreover, we also instantaneously transfected HeLa cells using siYY1 or CMV-YY1, together with pGL3Pro-G or -A or W-pro-G or -A. A similar result was obtained as previously, which showed that transcription factor YY1 had a much greater impact on the relative luciferase activity of G allele than A allele (Figures 6d-g ).
DISCUSSION
Previous studies have shown SNPs in WDFY4 or LRRC18 associated with SLE, 10,11 but the causative gene or functional variants remained unclear. Here, we demonstrated that a common intronic WDFY4 variant, rs877819 G 4A, influenced WDFY4 gene expression by affecting the binding of YY1. This finding may explain the mechanism of this SNP conferring susceptibility to SLE.
The zinc finger protein YY1 is a transcriptional activator or repressor of several genes, including some critical genes in B and T cells, which are central to the pathogenesis of autoimmune response. [14] [15] [16] For example, YY1 can enhance FCGR2B promoter activity by a functional promoter haplotype, which is also associated with SLE. 17 A genome-wide expression analysis revealed that YY1 may have a key role in the pathogenesis of multiple sclerosis or its subtypes. 18 In our study, we also showed that YY1 could have a role in transcription of WDFY4, with different affinity for a functional variant in the gene. However, whether and how the decreased expression of WDFY4 contributes to the pathogenesis of SLE still requires further research. An intron is not part of mature mRNA or a promoter complex; but it may still modulate DNA-protein interactions and affect gene expression. 12, 19, 20 Our study provides experimental evidence for the role of YY1 in autoimmune disease, and shows that YY1, a ubiquitously expressed transcription factor, can bind to the intronic SNP to affect the expression of WDFY4.
WDFY4 has multiple transcripts with unknown function, the longest transcript encodes 3184 amino acid residues. The human protein and that from other species show high sequence conservation (84% similarity with Bos taurus and Canis lupus familiaris, and 42% with Danio rerio).
11 Similar to its closest paralog, WDFY3, WDFY4 contains WD40 domains and a BEACH with a truncated FYVE zinc finger domain. Although little is known about this well-conserved protein, the gene is predominantly expressed in immune tissues such as lymph node, spleen, thymus and tonsil, thus it may be important in autoimmune disease.
In conclusion, we performed a functional analysis of WDFY4 and demonstrated that its downregulation may explain the increased risk of SLE. In addition, an intronic SNP, rs877819, may be the functional variant with the minor allele A, which is associated with decreased expression of WDFY4. Our findings may lend significant insight into the search for functional variants for understanding complex diseases.
MATERIALS AND METHODS

Patients and controls
We recruited 70 patients with SLE and 108 sex-and age-matched healthy controls, all from a Chinese Han population living in Jinan, China. All of the SLE patients fulfilled the American College of Rheumatology 1997 revised criteria for SLE. 21 Participants with other diseases or concurrent infection were excluded. Blood samples were obtained from all participants in this study after informed consent. The protocol of this study was approved by the ethics review committee for human studies at the School of Medicine, Shandong University.
Sequencing
All 61 exons of WDFY4 gene were sequenced in DNA samples from the 70 SLE cases to screen for genetic variants. The PCR reaction was run in a total volume of 50 ml solution containing 5 Â PCR buffer, 10 ml; 5 Â dNTP (1 mmol l À 1 each of dATP, dTTP, dGTP and dCTP), 10 ml; 50 ng genomic DNA; 0.4 mM of each primer and 1 U Taq DNA polymerase. The PCR
and a final extension at 72 1C for 10 min. All sequencing data were produced by the Genomic Analysis Facility (Huada, Shenzhen, China) and analyzed with the use of Chromas 2.33 (Technelysium Pty, South Brisbane, QLD, Australia).
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes by a standard phenol-chloroform method. Sanger sequencing was used for genotyping. Primers flanking the variant were designed with the use of Primer 5.0. PCR reaction and sequencing were performed as described previously.
Reverse transcriptase-PCR Total peripheral leukocyte RNA was extracted from 58 SLE patients and 58 healthy controls by the Trizol method (Invitrogen, Carlsbad, CA, USA), then underwent reverse transcription by the use of a kit (Takara, Otsu, Shiga, Japan). ASE for WDFY4 and LRRC18 were analyzed only in healthy controls. Complementary DNA (cDNA) was amplified by real-time PCR with an ABI 7500 real-time PCR system. The expression of GAPDH was measured as an internal control. Four duplicate wells were used for each subject.
Pyrosequencing
To test the ASE of rs7097397, we extracted total peripheral leukocyte RNA from 31 healthy controls heterozygous for rs7097397 by the Trizol method (Invitrogen), which underwent reverse transcription by the use of a kit (Takara). RNA samples were treated with RNase-free DNAase to eliminate genomic DNA contamination before being reverse-transcribed into cDNA. cDNA was amplified by PCR with transcript-specific primers. The average A/G cDNA expression ratio of each individual was normalized by the genomic DNA ratio from the same sample. Pyrosequencing involved the use of a PyroMark ID machine for three times for each sample. The A/(A þ G) ratio result of 0.5 indicated ASE negative ( À ), and 0.4-0.6, ASE positive ( þ ). 22 
Plasmid construction
To compare the relative expression of different alleles on rs877819, genomic fragments around the variant were amplified from subjects homozygous for rs877819, and cloned into the pGL3-promoter or -enhancer luciferase vector (Promega, Fitchburg, WI, USA) as pGL3Pro-G or -A and pGL3Enh-G. We also generated pGL3-basic-WDFY4-G or -A constructs (W-pro-G or -A) that contained the confirmed WDFY4 promotor sequence (800 bp from the transcription start site) and the genomic fragment of rs877819A or G. The above genomic fragments were inserted into a pGL3-basic vector as a negative control. The YY1 expression vector was kindly provided by Dr Naoko Tanese (NYU School of Medicine). All constructs were verified by direct sequencing.
Cell culture and transfection
HeLa and 293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. To detect allelic activity difference, the pGL3Pro-G or -A constructs were transiently transfected into the two cell lines with the use of Lipofectamine 2000, with a modified pRL-TK vector.
To determine the effect on allelic transcription activity of rs877819, HeLa cells were cotransfected by the use of Lipofectamine 2000 with the YY1 expressing vector or YY1 siRNA alone(5 0 -GCU AGA AUG AAG CCA AGA ATT-3 0 ), or combined with pGL3Enh-G or -A and a modified pRL-TK plasmid. A universal negative siRNA (5 0 -UUC UCC GAA CGU GUC ACG UTT-3 0 ) was used as control.
Dual-luciferase reporter assay
After transfection for 24 or 48 h, cells were extracted with lysis buffer, and relative dual-luciferase activity was measured by a dual-luciferase reporter assay system. The ratio of firefly to renilla luciferase was calculated for each well, with four duplicates for each sample.
Electrophoretic mobility shift assay HeLa cells (1 Â 10 7 ) were used for preparing nuclear protein extracts. For EMSA, double-stranded allelic probes containing rs877819 were An intronic variant associated with SLE H Zhao et al synthesized and labeled with digoxin. Conservative oligonucleotides for the transcription factors Freac2, ZBTB7 and YY1, and YY1 mutation probe were synthesized for competition assay. EMSA involved a gel-shift kit (Roche, Mannheim, Germany).
For supershift assay, a specific YY1 antibody (ab12132; Abcam, UK) was added to the binding reaction mixture. The YY1 consensus oligonucleotide was used as a labeled probe and as an unlabeled competitor in EMSA.
Chromatin immunoprecipitation assay
HeLa cells were crosslinked with 1.5% formaldehyde. The specific YY1 antibody or normal immunoglobulin G was used to immunoprecipitate protein-DNA complexes. Immunoprecipitated DNA was amplified by PCR with the following primer sequences: forward, 5
0 -TGGGAGCTAGGGAAG GA-3 0 , and reverse, 5 0 -TCAATGTGAGCCAAGAGC-3 0 , to produce an B200-bp fragment.
Western blot analysis
Equal amounts (40 mg) of extracts underwent 10% SDS-polyacrylamide gel electrophoresis, and then were transferred to a polyvinylidene difluoride membrane, which were incubated in nonfat milk in tris-buffered saline with Tween-20 (TBST; 0.1%) at room temperature for 1 h, and then immunoblotted with the primary antibodies for rabbit YY1 (ab109237; Abcam) and mouse anti-b-actin (Sigma) overnight at 4 1C. After a washing with TBST, membranes were incubated with secondary antibodies for 1 h at room temperature. Chemiluminescence detection involved the ECL PLUS kit (Amersham Biosciences, Sunnyvale, CA, USA).
Data analysis
Pairwise linkage disequilibrium (LD) was calculated by using the Haploview 4.2 program (http://www.broad.mit.edu/mpg/haploview/). Additional SNPs were imputed by IMPUTE2 using data from two Chinese GWAS. Data are expressed as mean ± s.d., and analyzed by Mann-Whitney U-test with the use of SPSS v10.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 4, v4.03 (GraphPad Software, La Jolla, CA, USA). The relative luciferase activities and mRNA expression levels were performed with Student's t-test. Po0.05 was considered statistically significant.
